Cargando…
Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288407/ http://dx.doi.org/10.1186/2051-1426-2-S3-P115 |
| _version_ | 1782351966059364352 |
|---|---|
| author | Subklewe, Marion Topp, Max Krupka, Christina Kufer, Peter Kischel, Roman Köhnke, Thomas Baeuerle, Patrick Zugmaier, Gerhard Frankel, Stanley Maniar, Tapan Newhall, Katie Spiekermann, Karsten Riethmueller, Gert Nagorsen, Dirk Hiddemann, Wolfgang |
| author_facet | Subklewe, Marion Topp, Max Krupka, Christina Kufer, Peter Kischel, Roman Köhnke, Thomas Baeuerle, Patrick Zugmaier, Gerhard Frankel, Stanley Maniar, Tapan Newhall, Katie Spiekermann, Karsten Riethmueller, Gert Nagorsen, Dirk Hiddemann, Wolfgang |
| author_sort | Subklewe, Marion |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4288407 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42884072015-01-15 Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia Subklewe, Marion Topp, Max Krupka, Christina Kufer, Peter Kischel, Roman Köhnke, Thomas Baeuerle, Patrick Zugmaier, Gerhard Frankel, Stanley Maniar, Tapan Newhall, Katie Spiekermann, Karsten Riethmueller, Gert Nagorsen, Dirk Hiddemann, Wolfgang J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288407/ http://dx.doi.org/10.1186/2051-1426-2-S3-P115 Text en Copyright © 2014 Subklewe et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Subklewe, Marion Topp, Max Krupka, Christina Kufer, Peter Kischel, Roman Köhnke, Thomas Baeuerle, Patrick Zugmaier, Gerhard Frankel, Stanley Maniar, Tapan Newhall, Katie Spiekermann, Karsten Riethmueller, Gert Nagorsen, Dirk Hiddemann, Wolfgang Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia |
| title | Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia |
| title_full | Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia |
| title_fullStr | Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia |
| title_full_unstemmed | Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia |
| title_short | Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia |
| title_sort | immunotherapy using bispecific t cell engager (bite(®)) antibodies: preclinical and clinical experience in acute leukemia |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288407/ http://dx.doi.org/10.1186/2051-1426-2-S3-P115 |
| work_keys_str_mv | AT subklewemarion immunotherapyusingbispecifictcellengagerbiteantibodiespreclinicalandclinicalexperienceinacuteleukemia AT toppmax immunotherapyusingbispecifictcellengagerbiteantibodiespreclinicalandclinicalexperienceinacuteleukemia AT krupkachristina immunotherapyusingbispecifictcellengagerbiteantibodiespreclinicalandclinicalexperienceinacuteleukemia AT kuferpeter immunotherapyusingbispecifictcellengagerbiteantibodiespreclinicalandclinicalexperienceinacuteleukemia AT kischelroman immunotherapyusingbispecifictcellengagerbiteantibodiespreclinicalandclinicalexperienceinacuteleukemia AT kohnkethomas immunotherapyusingbispecifictcellengagerbiteantibodiespreclinicalandclinicalexperienceinacuteleukemia AT baeuerlepatrick immunotherapyusingbispecifictcellengagerbiteantibodiespreclinicalandclinicalexperienceinacuteleukemia AT zugmaiergerhard immunotherapyusingbispecifictcellengagerbiteantibodiespreclinicalandclinicalexperienceinacuteleukemia AT frankelstanley immunotherapyusingbispecifictcellengagerbiteantibodiespreclinicalandclinicalexperienceinacuteleukemia AT maniartapan immunotherapyusingbispecifictcellengagerbiteantibodiespreclinicalandclinicalexperienceinacuteleukemia AT newhallkatie immunotherapyusingbispecifictcellengagerbiteantibodiespreclinicalandclinicalexperienceinacuteleukemia AT spiekermannkarsten immunotherapyusingbispecifictcellengagerbiteantibodiespreclinicalandclinicalexperienceinacuteleukemia AT riethmuellergert immunotherapyusingbispecifictcellengagerbiteantibodiespreclinicalandclinicalexperienceinacuteleukemia AT nagorsendirk immunotherapyusingbispecifictcellengagerbiteantibodiespreclinicalandclinicalexperienceinacuteleukemia AT hiddemannwolfgang immunotherapyusingbispecifictcellengagerbiteantibodiespreclinicalandclinicalexperienceinacuteleukemia |